Pyoderma gangrenosum: a review of pathogenesis and treatment
| Autor: | Deborah Negus, Christine S. Ahn, William W. Huang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Neutrophils T-Lymphocytes Immunology Inflammation Inflammatory bowel disease Pathogenesis 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Animals Humans Immunology and Allergy skin and connective tissue diseases Skin Crohn's disease business.industry fungi food and beverages Inflammasome Inflammatory Bowel Diseases medicine.disease Ulcerative colitis Dermatology Pyoderma Gangrenosum United States Infliximab 030220 oncology & carcinogenesis Cytokines medicine.symptom business Pyoderma gangrenosum medicine.drug |
| Zdroj: | Expert Review of Clinical Immunology. 14:225-233 |
| ISSN: | 1744-8409 1744-666X |
| DOI: | 10.1080/1744666x.2018.1438269 |
| Popis: | Pyoderma gangrenosum (PG) is a complex neutrophilic dermatosis that can occur as an idiopathic disease, in association with systemic conditions such as inflammatory bowel disease, as part of an inherited inflammatory syndrome. It can be challenging to treat, as it occurs in a wide variety of clinical settings and there is a lack of a standardized treatment approach. The main limitations to treatment have been an incomplete understanding of the pathogenesis. However, recent advances have been made in understanding the pathogenesis of this condition, and PG is now considered an autoinflammatory disease process. Areas covered: This review discusses the newest studies that further define our understanding of this disease and the relevant literature on treatment options for pyoderma gangrenosum. Expert commentary: The presence of abnormal neutrophils and T-cells lead to immune dysregulation, leading to lesions of PG. Increased levels of inflammatory mediators including IL-1β, IL-8, IL-17, and TNF-α contribute to the development of the disease but there are still several unknown factors, including the trigger for immune dysregulation and additional contributory components of the immune system. We provide our approach to the management of PG lesions, which involves a multi-faceted approach including wound care, topical therapy, and systemic medications in most cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|